<DOC>
	<DOCNO>NCT02462538</DOCNO>
	<brief_summary>This open label pilot study combine BV license indication imatinib patient ALCL . It intend `` window opportunity '' trial study drug give initial substitute conventional chemotherapy intention achieve remission enable patient proceed autologous allogeneic stem cell transplantation , eligible .</brief_summary>
	<brief_title>Brentuximab Vedotin Imatinib Patients With Relapsed Refractory ALK+ ALCL</brief_title>
	<detailed_description>Patients include trial relapse refractory ALK+ ALCL least one line conventional chemotherapy ineligible conventional chemotherapy . Imatinib give continuously start day 1 first cycle oral dose 100mg daily . The dose increase 200mg daily start day 1 second cycle DLT occur first cycle . BV give 3 weekly start day 1 dose 1.8 mg/kg body weight . In absence dose limit toxicity ( DLT ) i.e . haematological toxicity ≥ grade 2 , non- haematological toxicity ≥ grade 3 , 3 week therapy , presence clinical response ( CR PR ) cycle 1 , BV dose continue every 3 week 48 week . Dose modification stop rule introduce describe chapter 6 . In case progression time study patient go trial receive salvage treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients ≥ 18 year age ALK+ ALCL Histologically confirm relapse achieve PR CR conventional therapy Refractoriness conventional chemotherapy ( SD PD conventional chemotherapy ) Not able receive conventional chemotherapy ( e.g . due comorbidities ) Adequate organ function , define follow : Absolute neutrophil count ≥ 1,500/μL unless know hematologic/solid tumor marrow involvement Platelet count ≥ 75,000/ μL unless know marrow involvement disease Total bilirubin must &lt; 1.5 x upper limit normal ( ULN ) unless elevation know due Gilbert syndrome . ALT AST must &lt; 3 x upper limit normal range . AST ALT may elevate 5 time ULN elevation reasonably ascribe presence hematologic/solid tumor liver . Serum creatinine must &lt; 2.0 mg/dL and/or creatinine clearance calculate creatinine clearance &gt; 40 mL/minute . Hemoglobin must ≥ 8g/dL . Written , voluntarily sign informed consent Female patient either postmenopausal least 1 year screen visit surgically sterile childbearing potential , must practice 2 effective method contraception , time , time signing inform consent 6 month last dos BV last dos imatinib , whatever occurs later , agree completely abstain heterosexual intercourse . Male patient , even surgically sterilize , ( i.e. , status post vasectomy ) agree practice effective barrier contraception entire study period 6 month last dose BV , agree completely abstain heterosexual intercourse . Patient receive investigational treatment within 28 day study entry Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin imatinib ECOG performance status ≥ 3 Acute chronic infection Female patient pregnant breastfeed Known diagnosis HIV Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known cerebral meningeal disease ( HL etiology ) , include sign symptom PML Symptomatic neurologic disease compromise normal activity daily live require medication Any sensory motor peripheral neuropathy great equal Grade 2 Known history follow cardiovascular condition Myocardial infarction within 2 year study entry New York Heart Association ( NYHA ) Class III IV heart failure Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , electrocardiographic evidence acute ischemia active conduction system abnormalities Recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % Any active systemic viral , bacterial , fungal infection require systemic antibiotic within 2 week prior first study drug dose Diagnosed treat another malignancy within 3 year first dose previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>